Emergent BioSolutions – BioThrax

Emergent Biosolutions Inc pic

Emergent Biosolutions Inc
Image: emergentbiosolutions.com

As the executive chairman of the Board of Directors of Emergent BioSolutions Inc. in Gaithersburg, Maryland, Fuad El-Hibri is responsible for the development and manufacturing of vaccines and other treatments to fight diseases. Under the direction of Fuad El-Hibri, Emergent BioSolutions has manufactured an anthrax vaccine known as BioThrax.

Developed to help prevent anthrax, BioThrax has been tested in more than 25 studies and on over 500,000 people. Designed to be used prior to any exposure, the vaccine is approved for those between the ages of 18 and 65 who could be potential high-risk candidates. BioThrax can also be used after possible exposure to anthrax when used with recommended antibacterial drugs.

BioThrax works by stimulating the body’s immune system and helping to produce antibodies that protect against the protective antigen (PA) bacteria that carries the anthrax disease. By blocking the PA bacteria, it helps the body fight off the disease.

Advertisements

Emergent Biosolutions Begins Phase 1B Study of Potential Dengue Cure

Emergent Biosolutions Inc pic

Emergent Biosolutions Inc
Image: emergentbiosolutions.com

Business executive Fuad El-Hibri leads the board of trustees of El-Hibri Foundation, an organization focused on promoting peace and inclusivity in a diverse society. Besides his philanthropic work, Fuad El-Hibri chairs the board of directors of global biopharmaceutical company Emergent Biosolutions Inc.

In February 2017, Emergent Biosolutions Inc. announced it was beginning a Phase 1b study to assess how safe and tolerable UV-4B was. UV-4B is an antiviral under development as a potential treatment for the dengue virus. It works by targeting host glycosidase enzymes to reduce virus infectivity. If the trials are ultimately successful, the host-based action mechanism can be re-applied across a broad spectrum to treat other diseases such as SARS, Zika, and influenza.

Emergent’s Phase 1b study will enroll 40 adults from different US sites. The study is funded by the National Institute of Health’s Department of Health Human Services.

The Center for Disease Control estimates there are 100 countries affected by the deadly dengue epidemic, many of them in the tropics. These countries report up to 400 million new dengue infections annually, and there is no known cure for the disease.

Yale Healthcare Conference Encourages Discussion of Healthcare Issues